Ophthalmic PCD Pharma Franchise in India
Zexus Pharmaceuticals offers profitable ophthalmic PCD pharma franchise in India with a wide range of eye care products, exclusive rights, and strong business support.
Ophthalmic PCD Pharma Franchise in India (2025)
India’s eye care market is witnessing an incredible surge in 2025, driven by rising screen time, pollution levels, and an ageing population that demands quality eye care solutions. The growing awareness about eye health and the increasing prevalence of conditions like dry eyes, glaucoma, conjunctivitis, and diabetic retinopathy have created massive opportunities in the ophthalmic segment. For entrepreneurs seeking profitable business ventures, an Ophthalmic PCD Pharma Franchise in India presents an excellent opportunity with steady demand, recurring prescriptions, and specialized market positioning.
The story of eye care in India is particularly compelling. With roughly 30% of the world’s blind population residing in the country and about half of them losing vision due to preventable conditions like cataracts, the demand for ophthalmic medicines has never been higher. The Indian ophthalmology market, currently valued at approximately $1.3 billion, is projected to reach $34.3 billion globally by 2025, with India playing a significant role in this growth trajectory.
Introduction
The demand for eye care medicines and ophthalmic solutions in India has grown exponentially over the past few years. Factors contributing to this growth include increased screen exposure due to digital lifestyles, environmental pollution, diabetes-related eye complications, and better awareness about preventive eye care. This surge in demand makes the Ophthalmic PCD Pharma Franchise in India a highly attractive business proposition for both experienced pharmaceutical professionals and newcomers to the industry.
Why is PCD franchise in the ophthalmic segment particularly profitable? The answer lies in the nature of eye care treatments. Most ophthalmic conditions require continuous medication and regular follow-ups, creating a steady stream of repeat prescriptions. Unlike other pharmaceutical segments where patients might take medicine for a few days and recover, eye care often involves long-term management, ensuring consistent revenue for franchise partners.
Choosing the right pharma partner becomes crucial in this specialized segment because ophthalmic products require stringent quality standards, specialized manufacturing facilities, and deep understanding of eye care protocols. The wrong choice can lead to serious consequences for both patients and business reputation.
Top 10 Ophthalmic PCD Pharma Franchise in India
1) Zexus Pharmaceuticals
👉 Website: www.zexuspharma.com
“At Zexus Pharma, we don’t just make eye care medicines, we take care like its personal. For me, quality and trust comes first, then profit.” This personal approach has made Zexus Pharmaceuticals a standout choice for Ophthalmic PCD Pharma Franchise in India seekers.
Based on their comprehensive product portfolio, Zexus offers an impressive range of eye care solutions including antibiotic eye drops (Moxifloxacin 0.5%, Gatifloxacin 0.5%), lubricating drops (CMC 0.5% and 1%), anti-allergic formulations (Olopatadine 0.1%), anti-inflammatory drops (Ketorolac 0.5%), and specialized combinations for post-surgical care. Their product line also includes nutritional supplements like Astaxanthin, Lutein, and Zeaxanthin capsules for comprehensive eye health.
The company’s WHO-GMP certified manufacturing facilities ensure international quality standards, while their ISO certification demonstrates commitment to systematic quality management. What sets Zexus apart is their monopoly rights offering across multiple states, providing franchise partners with territorial exclusivity that protects investments and ensures sustainable growth.
2) Swissvision Healthcare
Swissvision has carved a niche in premium ophthalmic solutions with focus on innovative formulations and advanced delivery systems. Their product range caters to both therapeutic and preventive eye care needs.
3) Eyeris Vision Care
Specializing in comprehensive eye care solutions, Eyeris Vision Care offers a balanced portfolio covering common and complex ophthalmic conditions with emphasis on quality and affordability.
4) Mankind Pharma (Ophthalmic Division)
Mankind’s ophthalmic division brings the credibility of a pharmaceutical giant to eye care, offering reliable products backed by strong distribution networks and brand recognition.
5) Cipla Vision
Cipla’s vision care division leverages decades of pharmaceutical expertise to provide quality ophthalmic solutions trusted by healthcare professionals across India.
6) Sunways India Pvt. Ltd.
Known for their focus on specialized ophthalmic formulations, Sunways offers innovative solutions for various eye conditions with competitive pricing and reliable supply chains.
7) Micro Labs (Ophthalmology Division)
Micro Labs brings research-driven approach to ophthalmology with products designed to meet evolving needs of modern eye care practices.
8) Sentiss Pharma
Focusing on evidence-based ophthalmic solutions, Sentiss Pharma offers products that combine efficacy with safety for optimal patient outcomes.
9) Alcon Laboratories
As a global leader in eye care, Alcon’s presence in India provides franchise partners access to world-class ophthalmic products and technologies.
10) Intas Pharma (Ophthalmic Range)
Intas Pharma’s ophthalmic division offers comprehensive solutions covering therapeutic and surgical eye care needs with focus on innovation and quality.
New GST Rules 2025 for Ophthalmic Pharma Business
The Government of India’s revised GST structure for 2025 has brought significant benefits to the ophthalmic pharma sector, making the Ophthalmic PCD Pharma Franchise in India even more attractive from a business perspective.
Revised GST Slabs:
Most ophthalmic drugs including eye drops, lubricants, and antibiotic solutions now fall under 12% GST slab instead of the earlier 18%
Essential eye-care formulations like artificial tears and lubricating drops for dry eyes are classified under 5% GST
Cosmetic-based eye products such as premium eye serums continue to be taxed at 18% GST
Impact for Franchise Owners:
The lower GST rates translate into better profit margins for distributors. For example, an eye drop previously priced at ₹200 with 18% GST would cost customers ₹236. Under the new 12% structure, the same product costs ₹224, creating direct savings of ₹12 that can be shared between franchise partners and end customers, making products more competitive.
Simplified Compliance:
The new GST structure has also simplified Input Tax Credit (ITC) claims for pharma franchise partners, reducing compliance headaches under the new filing system. This means better cash flow management and reduced administrative burden for franchise owners.
Business Benefits:
- Improved price competitiveness in the market
- Better margin structures for sustainable growth
- Simplified tax compliance reducing operational overhead
- Enhanced ability to compete with unorganized sector players
Why Zexus Pharmaceuticals Stands First?
Zexus Pharmaceuticals has established itself as a leader in the Ophthalmic PCD Pharma Franchise in India space through several key differentiators:
Ethical Business Approach: The company’s commitment to putting quality and trust before profit has built lasting relationships with healthcare professionals and patients alike.
Consistent Quality: Their WHO-GMP certified facilities and rigorous quality control processes ensure that every product meets international standards. This consistency has made their products trusted by ophthalmologists across India.
Monopoly Rights: Zexus offers clear territorial rights to franchise partners, protecting investments and ensuring sustainable growth without internal competition.
Comprehensive Support: “We belive our partners are not just business dealers, but part of our family, and we help them even in understanding GST changes and market moves.” This holistic support approach includes training on product knowledge, market dynamics, regulatory compliance, and business development.
Product Innovation: Continuous research and development ensure that their product portfolio remains relevant and effective, giving franchise partners competitive advantages in the market.
How to Start an Ophthalmic PCD Pharma Franchise in India?
Investment Details:
Starting an Ophthalmic PCD Pharma Franchise in India typically requires an initial investment ranging from ₹1,00,000 to ₹5,00,000, depending on territory size and product portfolio selection. This includes initial stock, marketing materials, and working capital for the first few months of operations.
Licensing Requirements:
- Valid Drug License for pharmaceutical distribution
- GST registration for tax compliance and ITC benefits
- WHO-GMP certification preference for quality assurance
- Basic business registration and necessary permits
GST Registration Process:
With the new favorable GST rules, proper registration becomes even more critical. The process involves:
- Online application through GST portal
- Document verification including business registration, PAN, and address proofs
- Classification of products under correct HSN codes for tax benefits
- Setting up systems for regular compliance and ITC claims
Distribution Support & Product Selection:
Successful franchise partners focus on building comprehensive product portfolios that serve various ophthalmic needs. Key considerations include:
- Balancing therapeutic and preventive eye care products
- Ensuring adequate stock of fast-moving formulations
- Building relationships with ophthalmologists and optometrists
- Maintaining cold chain requirements where necessary
Conclusion
India’s eye care market is experiencing unprecedented growth, driven by demographic changes, lifestyle factors, and increased health awareness. The Ophthalmic PCD Pharma Franchise in India represents one of the most promising business opportunities in the pharmaceutical sector today.
Zexus Pharmaceuticals emerges as the top choice for franchise partners seeking reliable, quality-focused partnerships in the ophthalmic segment. Their comprehensive product range, ethical business practices, and strong support systems make them ideal for both experienced and new entrants to the franchise business.
Other established players like Swissvision Healthcare, Cipla Vision, and Intas Pharma also offer solid opportunities for entrepreneurs looking to build successful businesses in this growing market. The key lies in choosing partners who demonstrate consistent quality, provide adequate support, and offer products that truly address patient needs.
The new GST rules of 2025 have made the ophthalmic franchise business more profitable than ever before, with reduced tax burdens and simplified compliance requirements. Combined with the growing demand for eye care solutions, this creates an ideal environment for building sustainable, profitable businesses in the Ophthalmic PCD Pharma Franchise in India sector.
For entrepreneurs considering this opportunity, the time is right to enter this specialized yet rewarding market. With proper planning, the right partner selection, and dedicated execution, an ophthalmic franchise can become a highly successful and meaningful business venture that contributes to improving eye health across India.
Related Searches
